{
    "item_type": "proposal",
    "title": "Oral oxytocin for abdominal pain",
    "descriptions": [
        "Abstract:\n\nTitle: Oral Oxytocin for Abdominal Pain: A Paradigm Shift in Gastrointestinal Pain Management\n\nChronic abdominal pain, associated with conditions like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), affects over 10% of the global population and imposes a socio-economic burden of approximately €115 billion annually in Europe alone. Current treatments, which include poorly effective analgesics, often lead to adverse side effects and may exacerbate disease progression. Addressing this unmet medical need, our project \"Oral Oxytocin for Abdominal Pain\" aims to revolutionize chronic pain management through the development of a new class of gut-stable peptide analgesics specifically designed for oral administration.\n\nThe proposed project is poised to overcome the limitations of existing pain management strategies by focusing on the optimization of patented lead compounds that exhibit gut-specific action and negligible systemic off-target effects. This innovative approach holds the potential to fundamentally transform the treatment landscape for millions suffering from gastrointestinal disorders worldwide.\n\nThe primary goal is to advance these novel analgesics towards preclinical data generation, setting the stage for subsequent clinical translation. Proof-of-concept data will be essential in engaging industry partners, advancing drug candidates into the clinic, and ultimately providing a much-needed alternative to current therapeutic options.\n\nAnticipated outcomes include a significant reduction in the socio-economic burden caused by chronic abdominal pain, alongside a marked improvement in the quality of life for the affected population. Our project is not only a stride towards the scientific advancement of oral peptide drugs but also a step forward in the compassionate care of those burdened by gastrointestinal pain.\n\nThis grant proposal presents an opportunity to support a pivotal shift in chronic pain treatment, promising substantial benefits for patients and healthcare systems alike."
    ],
    "origin": "LLM",
    "llm_engine": "gpt-4-1106-preview",
    "generation_prompt_uid": "2b29516a26244cd709c58df739428c20",
    "generation_prompt_nickname": "from_json_details",
    "generation_prompt_text": "Write an abstract for a grant proposal based on the following details provided in JSON format. The JSON includes the title and key characteristics of the proposed project.\n\nPlease limit the response to 265 words or less.\n\n---\n\n**Description:**\n\n{'proposal_name': 'Oral oxytocin for abdominal pain', 'proposal_details': {'conditions': ['IBS', 'IBD'], 'affected_population_percentage': 10, 'socio_economic_burden_europe': 115000000000, 'currency': 'EUR', 'current_treatment_limitations': ['poorly effective analgesics', 'adverse effects', 'disease progression exacerbation'], 'project_goals': ['advance gut-stable peptide analgesics', 'optimize patented lead compounds', 'generate preclinical data', 'clinical translation'], 'innovation_aspects': ['gut-specific action', 'negligible systemic off-target effects', 'oral peptide drugs'], 'expected_outcomes': ['paradigm shift in chronic abdominal pain treatment', 'reduced socio-economic burden'], 'target_population': 'millions worldwide', 'descriptions': [{'summary': 'An innovative treatment strategy to create a new class of gut-stable peptide analgesics for the treatment of chronic abdominal pain with a focus on safety and efficacy.'}]}}\n\n**Description:**\n\n{'proposal_name': 'Oral oxytocin for abdominal pain', 'proposal_details': {'conditions_targeted': ['IBS', 'IBD'], 'affected_population': 'More than 10% of the global population', 'socio_economic_burden': '€115 billion/year in Europe', 'current_treatment_limitations': ['Poor effectiveness', 'Adverse effects', 'Potential exacerbation of disease'], 'project_goal': 'Advance a new class of gut-stable peptide analgesics', 'innovation': ['Gut-specific action', 'Negligible risk of systemic off-target effects', 'Oral peptide drugs'], 'objective': 'Optimise patented lead compounds towards oral drug candidates and generate preclinical data', 'outcome': 'Proof-of-concept data for clinical translation', 'industry_engagement_plan': 'Engage with industry partners and supporters to advance drug candidates into the clinic', 'potential_impact': ['Paradigm shift in treatment of chronic abdominal pain and gastrointestinal disorders', 'Improve quality of life', 'Reduce socio-economic burden'], 'descriptions': ['This project proposes the development of oral peptide drugs for the treatment of chronic abdominal pain associated with gastrointestinal disorders.']}}\n\n**Description:**\n\n{'proposal_name': 'Oral oxytocin for abdominal pain', 'proposal_details': {'conditions_targeted': ['IBS', 'IBD'], 'global_population_affected_percentage': 10, 'socio_economic_burden_europe': '€115 billion/year', 'pain_management_challenges': ['classical analgesics poorly effective', 'adverse effects', 'can exacerbate disease progression'], 'innovation': ['gut-stable peptide analgesics', 'gut-specific action', 'negligible risk of systemic off-target effects', 'oral peptide drugs'], 'project_objective': 'optimise patented lead compounds towards oral drug candidates and generate preclinical data for clinical translation', 'expected_outcome': ['proof-of-concept data', 'engagement with industry partners', 'advance drug candidates into the clinic'], 'potential_impact': ['treat chronic abdominal pain', 'improve quality of life', 'reduce socio-economic burden'], 'descriptions': ['Our gut-specific treatment approach along with this new class of analgesics could induce a highly desired paradigm shift in how to treat chronic abdominal pain and gastrointestinal disorders, an area with unprecedented unmet medical need.']}}"
}